Completed NA INTERVENTIONAL NCT00396916

Hybrid PET/CT in Cancer Patients

The Value of Novel Imaging Modality, Hybrid PET/CT, Using F18-Flurodeoxyglucose(FDG) in the Assessment of Cancer Patients. Impact of PET/CT on Clinical Management of Patients With Rising Tumor Markers and no Other Evidence of Disease and in Patients With Metastatic Cancer of Unknown Origin

Sponsor: Rambam Health Care Campus

Conditions Cancer

Interventions PET/CT imaging

Updated 5 times since 2017 Last updated: Apr 10, 2007 Started: Dec 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Cancer, this trial is completed. The trial is conducted by Rambam Health Care Campus and has accumulated 5 data snapshots since 2004. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA
Jan 2017 — Jun 2018 [monthly]

Completed NA

First recorded

Dec 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Rambam Health Care Campus

Data source: Rambam Health Care Campus

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Haifa, Israel